Abstract
Hyperaldosteronism alters cardiac function, inducing adverse left ventricle (LV) remodeling either via increased fibrosis deposition, mitochondrial dysfunction, or both. These harmful effects are due, at least in part, to the activation of the G protein-coupled receptor kinase 2 (GRK2). In this context, we have previously reported that this kinase dysregulates both β-adrenergic receptor (βAR) and insulin (Ins) signaling. Yet, whether aldosterone modulates cardiac Ins sensitivity and βAR function remains untested. Nor is it clear whether GRK2 has a role in this modulation, downstream of aldosterone. Here, we show in vitro, in 3T3 cells, that aldosterone impaired insulin signaling, increasing the negative phosphorylation of insulin receptor substrate 1 (ser307pIRS1) and reducing the activity of Akt. Similarly, aldosterone prevented the activation of extracellular signal-regulated kinase (ERK) and the production of cyclic adenosine 3′,5′-monophosphate (cAMP) in response to the β1/β2AR agonist, isoproterenol. Of note, all of these effects were sizably reduced in the presence of GRK2-inhibitor CMPD101. Next, in wild-type (WT) mice undergoing chronic infusion of aldosterone, we observed a marked GRK2 upregulation that was paralleled by a substantial β1AR downregulation and augmented ser307pIRS1 levels. Importantly, in keeping with the current in vitro data, we found that aldosterone effects were wholly abolished in cardiac-specific GRK2-knockout mice. Finally, in WT mice that underwent 4-week myocardial infarction (MI), we observed a substantial deterioration of cardiac function and increased LV dilation and fibrosis deposition. At the molecular level, these effects were associated with a significant upregulation of cardiac GRK2 protein expression, along with a marked β1AR downregulation and increased ser307pIRS1 levels. Treating MI mice with spironolactone prevented adverse aldosterone effects, blocking GRK2 upregulation, and thus leading to a marked reduction in cardiac ser307pIRS1 levels while rescuing β1AR expression. Our study reveals that GRK2 activity is a critical player downstream of the aldosterone signaling pathway; therefore, inhibiting this kinase is an attractive strategy to prevent the cardiac structural disarray and dysfunction that accompany any clinical condition accompanied by hyperaldosteronism.
Introduction
Aldosterone is a corticosteroid hormone synthesized by the adrenal cortex mainly in response to renin–angiotensin system (RAS) activation and by high potassium (K+) levels (; ). Importantly, aldosterone activities were initially perceived as confined to a few organs, especially to the distal tubule and collecting duct of the nephrons in the kidney (; ). However, the demonstration of specific aldosterone binding to its cytoplasmic/nuclear mineralocorticoid receptor (MR) in disparate areas of the cardiovascular system has widened the range of aldosterone targets (; ; ; ). It is now consolidated, for instance, that this hormone controls the function and the growth, as well as the metabolism of several cell types, including cardiomyocytes, fibroblasts, and vascular cells (; ; ; ; ). This evidence has advanced aldosterone and its receptors to a new frontline for treating heart failure (HF), i.e., to prevent its onset or to arrest its progression (; ; ; ; ). Consistent with this new scenario, high aldosterone levels, and the subsequent MR hyperactivation, have been associated to the onset of insulin resistance, which is a well-recognized risk factor of cardiovascular disease (CVD) (; ). More in detail, in vascular smooth muscle cells (VSMCs) and in adipocytes, aldosterone has been shown to inhibit insulin receptor substrate-1 (IRS1) that is considered a second messenger of the insulin receptor, thus preventing Akt activation and glucose uptake (; ). Moreover, recent studies have demonstrated that, in fibroblasts, MR inhibition is able to prevent pro-fibrotic βAR activation (; ) and, as previously seen in the heart, aldosterone can both augment the hypertrophic response and myocardial apoptosis and fibrosis (; ). In this context, we have recently reported that, downstream of the aldosterone/MR system, there is the activation of G protein-coupled receptor kinase 2 (GRK2) and GRK5 (). Accordingly, both in vitro and in vivo, we have found that aldosterone stimulation induces cardiac GRK2 activation, followed by increased cell death and mitochondrial dysfunction. Conversely, aldosterone-mediated GRK5 activation results in an increased pathological hypertrophy (). Of note, GRK2 has been discovered as a regulator of cardiac contractility via β-adrenergic receptor (βAR) phosphorylation and subsequent desensitization in response to catecholamine stimulation (). However, in HF, a condition characterized by increased sympathetic nervous system activation (SNS), GRK2 activity/expression is upregulated, and this elevation in GRK2 activity has many adverse effects in the cardiovascular system because it induces massive βAR downregulation, with consequent left ventricular (LV) dysfunction (). Intriguingly, in addition to these canonical effects, GRK2 inhibits also IRS1, via direct binding and subsequent phosphorylation at the serine in position 307 thus leading to an impaired Akt activity (; ; ). Despite all this evidence, it remains to be determined still if aldosterone influences cardiac insulin signaling and βAR function and if this eventual modulation requires GRK2. Hence, in the present study, we tested the impact of aldosterone stimulation, and the role of GRK2, on both insulin and βAR signaling in vitro, in fibroblasts (3T3 cells), and in vivo, in mice undergoing chronic aldosterone infusion or surgical-induced myocardial infarction (MI), two models of hyperaldosteronism ().
Materials and Methods
Agonists and Inhibitors
Aldosterone (A9477), spironolactone (S3378), insulin (I2643), and isoproterenol (ISO) (I5627) were purchased from Sigma-Aldrich (St. Louis, MO, USA). CMPD101 (HB2840) was purchased by Hello Bio (Bristol, UK).
Cell Culture and Stimulation Conditions
3T3-L1 fibroblasts were purchased from ATCC (ATCC® CL-173™) and cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% P/S. Prior to stimulation, all the cells were starved with serum-free media. A group of cells was serum-starved for 12 h and then was stimulated with aldosterone (1 µM) at different time points in fresh serum-free media. Another group of cells was serum-starved for 1 h and then, under this condition, was pretreated with aldosterone (1 µM) and/or CMPD101 (3 µM) for additional 12 h, as previously done by us (). Then, the cells have been stimulated with insulin (100 nm) or ISO (10 µM) dissolved in fresh serum-free media. Control unstimulated cells were maintained in serum-free media.
Immunoblots
Cells (fibroblasts) and left ventricular (LV) samples were lysed in a RIPA buffer with protease (cOmplete-Roche, USA) and phosphatase inhibitor (PhosSTOP-Roche, USA) cocktail (Roche). Protein samples were quantified using a DC™ Protein Assay (Bio-Rad) and read at 750 nm using an iMark microplate reader (Bio-Rad). Then proteins (40 µg) were separated by 4–20% Sodium Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis (SDS-PAGE) (Invitrogen) and were transferred to PVDF membrane (Bio-Rad). After blocking, with milk 5% in TBS-Tween 0.1%, the membranes were incubated and probed with the first antibody at 4°C overnight according to manufacturer’s instructions. Then, the proteins were probed with a corresponding secondary antibody, followed by the visualization of the proteins with a chemi-doc XRS system (Bio-Rad), and quantitative densitometric analysis was performed using the chemi-doc XRS imaging software. Protein levels of a) GRK2 (sc-562, C-15, Santa Cruz Biotechnology, 1:1,000; 05-465, Millipore, 1:1,000); b) GAPDH (sc-32233, 6C5, Santa Cruz Biotechnology, 1:2,000); c) phosphor-ERK (extracellular signal-regulated kinase) 1/2 (#9106, Cell Signaling, 1:1,000), total ERK 1/2 (#9102, Cell Signaling, 1:1,000); d) phospho-Akt (pAkt, sc-514032, Santa Cruz Biotechnology, 1:1,000); e) total Akt (sc-8312, Santa Cruz Biotechnology, 1:1,000); f) phospho-IRS1 (Ser307pIRS1, #05-1087, Millipore, 1:1,000); g) total IRS1 (tIRS1, sc-515017, Santa Cruz Biotechnology, 1:1,000); and h) β-1 adrenergic receptor (β1AR, PA1-049, Invitrogen, 1:1,000) were assessed.
Cyclic Adenosine 3′,5′-Monophosphate (cAMP) Assay
cAMP levels were assessed using a commercial kit (Cayman chemical—501001), following the manufacturer’s instructions. Briefly, 3T3-L1 fibroblasts were plated in six-well multi-well, and after stimulation, the cells were lysed in 250 μl of 0.1-M HCl. Then, after centrifugation (1,000 g for 10 min), the resulting supernatants were quantified with a DC™ Protein Assay (Bio-Rad) to assess equal protein concentration. Then, the plate was read at 415 nm using an iMark microplate reader (Bio-Rad). Fifty microliters of the lysate were used to perform the enzyme-linked immunosorbent assay (ELISA) assay.
Animal Models
All animal procedures were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of Temple University Lewis Katz School of Medicine. We used wild-type (WT) mice, mice bearing floxed grk2 (grk2-fl/fl), and cardiac-specific GRK2 knockout (KO) mice, generated breeding αMHC-Cre mice with grk2-fl/fl (). All animals (males and females, 9–10 weeks) were maintained on a C57Bl/6 background.
Experimental Procedure:Pump implantation—Mice were anesthetized with isoflurane [2.5% (vol/vol)] and mini-osmotic pumps (1004, ALZET, DURECT Co., Cupertino, USA), loaded with Phosphate-buffered saline (PBS) and 5% ethanol (vehicle); aldosterone (2 μg·mouse·day−1) and spironolactone (20 mg·kg−1·day−1) were implanted subcutaneously through a subscapular incision, which was then closed using 3.0 silk suture (Ethicon), as previously described (Cannavo et al, 2016; Tian et al., 2009). After 4 weeks of infusion, transthoracic echocardiography was performed, and then blood samples were collected by puncturing the heart, and after euthanasia, the heart was explanted and excised for pathological examination and immunohistochemistry.
Myocardial Infarction (MI)—Surgically induced MI was performed in WT mice (C57BL6, 9-week-old both females and males) as previously described (). One-day post-MI, mice were randomly assigned to one of the following groups: MI and MI + spironolactone (MI + Spiro). Sham-operated animals were used as control.
Echocardiography
Transthoracic echocardiography was performed in all experimental groups (vehicle and aldosterone infused; sham-operated, MI, and MI + Spiro) to assess cardiac structure and function at baseline and at the end of the study period (4 weeks), using a VisualSonics VeVo 2100 system (VisualSonics, Toronto, Canada), as previously described (). No gender-dependent differences were observed in terms of basal, post-MI, or post-aldosterone cardiac function.
Histology
Cardiac specimens were fixed in 4% formaldehyde and embedded in paraffin. After deparaffinization and rehydration, 5-μm-thick sections were prepared and mounted on glass slides.
Picro-Sirius Red Staining—Cardiac sections were stained with 1% Sirius Red in picric acid (Sigma-Aldrich, St. Louis, Missouri) to detect interstitial fibrosis and to calculate infarct size (). The percentage of fibrosis and the infarct size were quantified using a software (ImageJ). Cardiac fibrosis images were acquired using a BA410 microscope (Motic®). For each of the samples, five to six fields (∼400–900 cells for field) were acquired to detect fibrotic areas.
TUNEL staining—Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) was performed on fixed paraffin-embedded LV sections using a commercial kit (Roche), and the assay was performed according to manufacturer’s instructions. Finally, cardiac sections were mounted with Fluoroshield with 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, St. Louis, Missouri). Fluorescent images were acquired using a ZOE™ Fluorescent Cell Imager (Bio-Rad). For each of the samples, five to six fields (∼400–900 cells for field) were acquired.
Analysis and Statistics
All experimental procedures (in vitro and in vivo) were performed in a blinded fashion. Data are expressed as means ± SE. Statistical significance was determined by a Student t-test or Mann–Whitney U exact test when the sample size was <10. For multiple comparisons, one-way analysis of variance with Dunnet’s or Tukey’s post hoc tests was performed. All data were analyzed using GraphPad Prism software version 8 (GraphPad Software, La Jolla, California). Statistical significance was accepted at p < 0.05.
Results
GRK2 Signaling Downstream of Aldosterone/MR System Impairs Insulin Signaling in 3T3 Fibroblasts
In adipocytes and in VSMCs, aldosterone blocks insulin signaling, contributing to insulin resistance (; ). Yet, whether GRK2 has a role in this chain of events remains untested. Therefore, to fill this gap in knowledge, we stimulated 3T3 cells with aldosterone (1 µM) at different time points (15 min, 30 min, 6 h, and 12 h) to analyze the expression levels of GRK2. Surprisingly, GRK2 protein levels were increased as early as 15 min after the aldosterone stimulation initiation, and they remained elevated at 30 min, 6 h, and 12 h, compared with those in unstimulated cells (NS) that exhibited no change in the expression of this kinase between these same time points (Figures 1A, B). Of note, mRNA transcript levels for GRK2 were not elevated over control levels 15–30 min or 6 h after aldosterone stimulation (Supplementary Figure 1). A marked elevation in GRK2 mRNA levels was evident only after 12 h of aldosterone stimulation (Supplementary Figure 1). This evidence is entirely consistent with previous reports from Cipolletta and coworkers () who demonstrated that, following acute ISO or insulin stimulation, GRK2 is markedly upregulated, thus corroborating the notion that this kinase is critical for the regulation of physiological pathways governed by either GPCR- or non-GPCR-related factors. Furthermore, we have previously reported that 30-min stimulation with aldosterone is sufficient to phosphorylate GRK2 at the serine 670 site (s670pGRK2), inducing the translocation of the kinase to the mitochondria. On these grounds, we next analyzed the phosphorylation levels of GRK2 and found that these levels varied with time (Figure 1C). More in detail, from 15 to 30 min after aldosterone stimulation initiation, s670pGRK2 amounts were markedly elevated over control levels. However, already 6 or 12 h after aldosterone superfusion, the extent of s670pGRK2 sharply declined (Figure 1C). In aggregate, this set of data suggests that, upon aldosterone stimulation, GRK2 is able to deploy both its more canonical effects, such as regulating plasma membrane receptor function, i.e., βAR signaling, and noncanonical actions, such as those due to its translocation to mitochondria where the kinase can bind to non-GPCR-related molecular entities (; ).
Figure 1
Based on the previously reported findings, we next set out to evaluate the impact of aldosterone/GRK2-dependent signaling on insulin and βAR receptor-dependent pathways. To this end, a group of cells was pretreated with the GRK2 inhibitor, CMPD101 (3 µM) (; ), in the presence or absence of aldosterone (1 µM). Then, these cells were stimulated with insulin (100 nM, for 15 min) and tested for the phosphorylation levels of IRS1, at the serine 307 (s307pIRS1). This is a well-consolidated site targeted by GRK2 that, upon phosphorylation, shuts down the insulin signaling (). We also analyzed the activation of Akt by monitoring its phosphorylation at serine 473 (ser473pAkt). As shown in Figures 1D, E, as compared with unstimulated cells (NS), insulin did not increase the amount of s307pIRS1 but induced a sustained activation of Akt. In stark contrast, aldosterone treatment markedly elevated s307pIRS1 levels while reducing Akt activity of Akt in response to insulin (Figures 1D, E). Of relevance, the detrimental effects exerted by aldosterone on insulin signaling were blunter by pretreating cells with the GRK2 inhibitor, CMPD101 (Figures 1D, E). It is worth stressing that neither CMPD101 nor aldosterone (taken singularly) had any influence on the mediators (Akt) of insulin signaling (Supplementary Figures 2A, B).
Finally, we tested the impact of spironolactone, an MR antagonist, previously found to block the upregulation of GRK2 as well as its deleterious effects in response to the activation of aldosterone/MR system (). To this aim, a group of 3T3 cells was pretreated with spironolactone (10 µM for 30 min) prior to aldosterone and/or insulin treatment. Insulin stimulation induced a robust Akt activation, and the treatment with the mineralocorticoid hormone blunted this effect (Supplementary Figure 3A).
Aldosterone Alters βAR Signaling in 3T3 Fibroblasts via GRK2 Activation
A correlation exists between aldosterone and βAR activation (; ). More in detail, in experimental models of LV dysfunction based on the chronic infusion of ISO, either spironolactone or eplerenone effectively prevents ISO-triggered collagen deposition (; ). Interestingly, none of these studies, however, have tested whether MR antagonism also prevents βAR dysfunction due to chronic ISO administration as well as whether chronic MR activation has an impact on βAR function and GRK2 upregulation. To fill these critical gaps in knowledge, we examined the effect of aldosterone on βAR function in vitro, using 3T3 cells, assessing the activation status of the ERK that is a useful marker of βAR signaling (). To this end, the cells, either unstimulated (NS) or stimulated with ISO (10 µM for 10 min), were pretreated with aldosterone (1 µM for 12 h) and/or with CMPD101 (3 µM). As shown in Figure 2A, in response to ISO, we observed a robust ERK activation (pERK) compared with NS cells, which was blocked entirely by aldosterone pretreatment. Nonetheless, pretreatment of cells with CMPD101 significantly abolished the effects of aldosterone and resulted in enhancement of ERK activation in response to ISO. Next, we analyzed the effects of aldosterone on the production of cAMP that is typically elevated after βAR stimulation (). Importantly, we observed that ISO induced a significant rise in cAMP levels, but this effect was abolished by aldosterone pretreatment (Figure 2B). Further, the inhibition of GRK2 had a positive influence on the cAMP formation, thus preventing the harmful effects of aldosterone on βARs. Interestingly, neither CMPD101 nor aldosterone alone had a sizable impact on ERK phosphorylation (Supplementary Figures 4A, B) and cAMP formation/accumulation (Figure 2B). These data support the notion that aldosterone impairs βAR function and that GRK2 is a crucial component of aldosterone-mediated adverse effects.
Figure 2
Chronic in Vivo Infusion of Aldosterone Upregulates GRK2 in the Heart
Hyperaldosteronism is a condition that usually precedes or occurs after MI, precipitating LV dysfunction and remodeling (; ; ). Importantly, chronic (4 weeks) administration of aldosterone (2 µg·mouse·day-1) results in a significant increase in myocyte GRK2 expression and mitochondrial activity, along with augmented cell death and fibrosis, as recently shown by our group (). Yet, whether Aldo impairs insulin signaling and βAR function in the mouse heart, in vivo, remains to be directly tested. Thus, to translate our in vitro findings to in vivo clinically relevant situations, we subjected Normal Littermate Control (NLC) (WT) and cardiac-specific GKR2 knockout (cGRK2KO) mice to a 4-week continuous infusion of aldosterone. A group of mice was infused with vehicle solution as a control. We found that in NLC mice, this intervention elicited a marked rise in GRK2 protein levels in LV lysates, as compared with those in vehicle-treated animals (Figure 3A). This change was accompanied by a prominent surge in cardiac ser307pIRS1 levels and by marked downregulation of β1AR density (Figures 3B, C). Importantly, the deleterious effects associated with aldosterone stimulation were utterly blunted in cGRK2KO mice (Figure 3). Indeed, in the presence of low GRK2 expression (Supplementary Figure 5), aldosterone stimulation failed to either increase ser307pIRS1 levels or reduce β1AR density. Thus, these data attest that GRK2 is chiefly involved in the in vivo signaling effects elicited by chronic aldosterone stimulation.
Figure 3
MR Antagonism by Spironolactone Prevents Postischemic Cardiac Insulin Resistance and β1AR Dysfunction Thus Preventing HF Onset
MR blockade, either via spironolactone or eplerenone treatment, prevents Aldo-induced increment in GRK2 expression and activity (). However, whether spironolactone exerts its protective, anti-ischemia effects, at least in part, through the inhibition of GRK2, and thus restoring cardiac insulin and/or β1AR sensitivity, is currently unknown.
To address these questions, MI was surgically induced in mice via coronary artery ligation (). One-day after MI, mice were treated with spironolactone (20 mg·kg·day−1) for the entire study period (4 weeks). Sham-operated animals were used as controls. The echocardiographic analysis was performed at baseline and 4 weeks post-MI (Figure 4A).
Figure 4
As shown in Figure 4B, MI-inflicted mice displayed a marked deterioration of LV function compared with Sham animals, as indexed by percentage fractional shortening (%FS). Conversely, spironolactone-treated MI mice had significantly ameliorated LV dysfunction and reduced infarct size (Figures 4B, C). In a consistent manner, at the tissue level, myocytes from untreated MI mice harbored prominent cardiac fibrosis, assessed by picro-sirius red staining (Figure 4D), and augmented myocardial cell death, as per TUNEL staining (Figure 4E). It is worth noting that all these adverse effects were significantly blunted in MI mice receiving spironolactone (Figures 4D, E). Intriguingly, at the molecular level, the marked MI-dependent GRK2 upregulation was prevented by this MR antagonist (Figure 5A). Consistently, augmented levels of ser307pIRS1 and reduced β1AR expression, accompanying the increased GRK2 activity and attesting insulin signaling dysfunction and β1AR downregulation, were also significantly attenuated by spironolactone (Figures 5B, C). Thus, MR antagonism by spironolactone ameliorates post-MI LV dysfunction, improving, among other possible beneficial effects, insulin resistance and β1AR dysfunction.
Figure 5
Discussion
SNS and RAS are well-recognized primary pathogenic drivers of HF (). Accordingly, most of the agents that block the activation of these systems are part of the current HF therapeutic armamentarium [i.e. β-blockers, Angiotensin II receptor (AT1R) blockers, ACE inhibitors, and MR antagonists] (; ; ). However, since not all patients can benefit from these drugs, there is a keen interest in the identification of additional, specific strategies able to block the hyperactivity of these noxious systems (). Importantly, MR antagonists have shown to be therapeutic and safe in a wide range of HF patients with reduced EF, both symptomatic (in NYHA class III and IV) () and in asymptomatic or mildly symptomatic (in NYHA class I and II) (Zannad et al., 2011). Indeed, these therapeutic agents are currently indicated in the majority of HF patients; thus, the interest in the mechanism beyond MR inhibition is continuously growing.
In this context, we have recently revealed novel mechanisms whereby aldosterone may affect cardiac function (). More in details, we have found that the adverse effects of aldosterone on cardiomyocytes are not exclusively mediated by MR activation but also mediated by GRK2 (). Importantly, this kinase is centrally involved in MR-mediated cardiac toxicity that is negatively affecting mitochondrial function and survival of cardiomyocytes. Moreover, in the present study, our data add new important pieces to the mosaic of how aldosterone/GRK2 system impacts on cardiac function and remodeling (Figure 6). In this context, we have found that aldosterone negatively affects insulin and β1AR function both in vitro in 3T3 cells and in vivo in the hearts of two murine models of hyperaldosteronism (aldosterone-infused or infarcted mice). Moreover, we have demonstrated that such mechanism appears to be orchestrated by GRK2. More in detail, we have shown in 3T3 cells that soon after (15 and 30 min) aldosterone stimulation initiation, GRK2 becomes upregulated and phosphorylated at s670, which is in line with our previous report in cardiomyocytes (). However, GRK2 expression levels remain high even only up to 12 h. After that, the amount of the kinase phosphorylation comes back to control levels. This evidence suggests that, upon phosphorylation, GRK2 is able to both translocate to mitochondria, following phosphorylation, and to bind plasma membrane receptor when unphosphorylated, as previously reported (; ; ). In the same vein, here we demonstrate that, after chronic aldosterone treatment of 3T3 cells, a prominent inhibition of insulin signaling occurs, as documented by the increased s307pIRS1 levels and a subsequent reduction in s473pAkt levels, followed by the marked impairment of the βAR function with a consequent decrease of ERK activation and cAMP production in response to ISO stimulation. Interestingly, the usage of the GRK2 inhibitor, CMPD101, markedly blunted the effects of aldosterone, preventing both insulin and βAR signaling dysfunction.
Figure 6
Next, we aimed at confirming the in vitro findings in an in vivo model of hyperaldosteronism, such as the chronic (4 weeks) continuous infusion of aldosterone in mice, as done previously (). With this tool in hand, we demonstrated that aldosterone increased cardiac s307pIRS1 levels and caused a massive β1AR downregulation in NLC mice but not in cGRK2KO mice. This evidence goes hand in hand with previous findings showing that cGRK2KO hearts were functionally and structurally protected against hyperaldosteronism ().
Finally, our results that were obtained in infarcted mice with the MR antagonist, spironolactone, which has previously been attested as a blocker of aldosterone-dependent GRK2 upregulation, consolidate the idea of the potential GPCR dependence into the pathological effects induced by aldosterone.
More in details, our data demonstrate that following MI, GRK2 levels are significantly increased while insulin and β1AR signaling pathway are impaired. Conversely, spironolactone treatment is able to mitigate such noxious aldosterone activities and to prevent both IRS1 negative phosphorylation, β1AR downregulation, and GRK2 upregulation. Interestingly, all the beneficial effects of spironolactone correlated with the preserved cardiac function and better remodeling parameters markedly deteriorated by MI.
Limitations
One limitation of our study is the lack of a randomization parameter for the MI studies. One day after MI, we randomly assigned the mice to spironolactone or vehicle treatment, performing an echocardiographic analysis only at baseline (before MI) and at the end of the study period. Although we did not check the degree of the infarct size in the two groups, at 1-day post-MI, we are confident that the infarct area was homogeneous between the animals. Indeed, we have long-standing expertise on in vivo MI, and our method has been proven to inflict a very reproducible infarct size (). Moreover, in studies in which we checked for cardiac function after randomization, we did find a statistically significant difference among post-MI randomized groups (). Therefore, the effects seen with the different treatments are not due to an unequal initial magnitude of the infarct lesion. Another limitation of the present study is the lack of data regarding the effects of aldosterone on the β2AR signaling pathway. However, β1AR signaling is the major isoform expressed in cardiomyocytes, liable for the main actions of the βAR system on the cardiac function and tightly regulated by GRK2. Future, in-depth studies shall address the impact of aldosterone on the β2AR signaling in cardiomyocytes, fibroblasts, and endothelial cells. Indeed, this receptor subtype is much less expressed at cardiomyocyte level, but it is also targeted by GRK2; therefore, aldosterone may also alter β2AR-dependent cardiac cell functions.
Conclusion
Previous evidence has attested that an association exists between aldosterone and insulin signaling dysfunction. However, no studies have assessed the relevance of this cross talk on heart function. Nor have studies clarified whether GRK2, a primary cardiac regulator of IRS1, has any role in the way aldosterone influences the insulin signaling and also in βAR-mediated modulation of myocardial function and response to ischemic stress. Here, we fill these gaps in knowledge by demonstrating, for the first time, that canonical and noncanonical actions of GRK2 account for aldosterone-triggered attenuation of insulin- and βAR-mediated effects at the heart levels. Several clinical cardiovascular disorders are characterized by a persistently elevated “aldosterone tone”; see, for instance, the hypertensive or the HF syndrome. In light of this, the current evidence showing that, in infarcted mice, the MR blocker, spironolactone, offsets aldosterone-induced cardiac insulin-signaling dysfunction and β1AR downregulation by blunting canonical (and likely noncanonical) effects mediated by GRK2 levels suggests the unique opportunity of combining the benefits of a direct MR antagonism to those elicited by the pharmacological inhibition of GRK2, a novel, highly translational perspective that warrants further, in-depth investigation.
Funding
This research was partly funded by: STAR program 2017 L1— Compagnia San Paolo and Federico II University of Naples and Italian Ministry of Education, Universities and Research- ”Rita Levi Montalcini 2016” (to ACa); CardioPaTh PhD program (to FM); NIH_NHLDBI R01HL136918 and Magic- That-Matters (JHU) (to NP).
Statements
Ethics statement
All animal procedures were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of Temple University Lewis Katz School of Medicine.
Author contributions
ACa, FM, and GR designed, analyzed data, and wrote the manuscript. ACa, LB, FM, AE, DL, GG, and CP performed the experiments. AR, ACi, NF, NP, and WK revised the manuscript.
Conflict of interest
NF and GR provide scientific advice to Istituti Clinici Scientifici ICS Maugeri SpA, Società Benefit, Scientific Institute of Telese Terme, Benevento, Italy.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2019.00888/full#supplementary-material
References
1
BouleyR.WaldschmidtH. V.CatoM. C.CannavoA.SongJ.CheungJ. Y.et al. (2017). Structural determinants influencing the potency and selectivity of indazole-paroxetine hybrid G protein-coupled receptor kinase 2 inhibitors. Mol. Pharmacol.92 (6), 707–717. doi: 10.1124/mol.117.110130
2
BrillaC. G.MatsubaraL. S.WeberK. T. (1993). Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J. Mol. Cell. Cardiol.25, 563–575. doi: 10.1006/jmcc.1993.1066
3
CannavoA.LiccardoD.KochW. J. (2013). Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapy. Front. Physiol.4, 264. doi: 10.3389/fphys.2013.00264
4
CannavoA.LiccardoD.EguchiA.ElliottK. J.TraynhamC. J.IbettiJ.et al. (2016). Myocardial pathology induced by aldosterone is dependent on non-canonical activities of G protein-coupled receptor kinases. Nat. Commun.7, 10877. doi: 10.1038/ncomms10877
5
CannavoA.RengoG.LiccardoD.PunA.GaoE.GeorgeA. J.et al. (2017). β1-blockade prevents post-ischemic myocardial decompensation viaβ3AR-dependent protective sphingosine-1 phosphate signaling. J. Am. Coll. Cardiol.70, 182–192. doi: 10.1016/j.jacc.2017.05.020
6
CannavoA.BencivengaL.LiccardoD.EliaA.MarzanoF.GambinoG.et al. (2018a). Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology. Oxid. Med. Cell. Longev.1204598. doi: 10.1155/2018/1204598
7
CannavoA.KomiciK.BencivengaL.D’amicoM. L.GambinoG.LiccardoD.et al. (2018b). GRK2 as a therapeutic target for heart failure. Expert Opin. Ther. Targets22, 75–83. doi: 10.1080/14728222.2018.1406925
8
CiccarelliM.ChuprunJ. K.RengoG.GaoE.WeiZ.PeroutkaR. J.et al. (2011). G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation123, 1953–1962. doi: 10.1161/CIRCULATIONAHA.110.988642
9
CipollettaE.CampanileA.SantulliG.SanzariE.LeoscoD.CampigliaP.et al. (2009). The G protein coupled receptor kinase 2 plays an essential role in beta-adrenergic receptor-induced insulin resistance. Cardiovasc. Res.84 (3), 407–415. doi: 10.1093/cvr/cvp252
10
D’AddioG.CorbiG.CesarelliM.RengoG.FurgiG.FerraraN. (2017). Aging and cardiac autonomic control in chronic heart failure: methods and clinical implications. J. Gerontology Geriatrics65, 38–47.
11
DooleyR.HarveyB. J.ThomasW. (2012). Non-genomic actions of aldosterone: from receptors and signals to membrane targets. Mol. Cell. Endocrinol.350, 223–234. doi: 10.1016/j.mce.2011.07.019
12
EspositoG.PerrinoC.CannavoA.SchiattarellaG. G.BorgiaF.SanninoA.et al. (2011). EGFR trans-activation by urotensin II receptor is mediated by β-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. Basic Res. Cardiol.106, 577–589. doi: 10.1007/s00395-011-0163-2
13
GaoE.LeiY. H.ShangX.HuangZ. M.ZuoL.BoucherM.et al. (2010). A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ. Res.107, 1445–1453. doi: 10.1161/CIRCRESAHA.110.223925
14
Garcia-GuerraL.Nieto-VazquezI.Vila-BedmarR.Jurado-PueyoM.ZalbaG.DíezJ.et al. (2010). G protein-coupled receptor kinase 2 plays a relevant role in insulin resistance and obesity. Diabetes59, 2407–2417. doi: 10.2337/db10-0771
15
HeB. J.JoinerM. L.SinghM. V.LuczakE. D.SwaminathanP. D.KovalO. M.et al. (2011). Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat. Med.17, 1610–1618. doi: 10.1038/nm.2506
16
HitomiH.KiyomotoH.NishiyamaA.HaraT.MoriwakiK.KaifuK.et al. (2007). Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension50, 750–755. doi: 10.1161/HYPERTENSIONAHA.107.093955
17
HoriY.ToueiD.SaitohR.YamagishiM.KanaiK.HoshiF.et al. (2017). The aldosterone receptor antagonist eplerenone inhibits isoproterenol-induced collagen-I and 11β-HSD1 expression in rat cardiac fibroblasts and the left ventricle. Biol. Pharm. Bull.40, 1716–1723. doi: 10.1248/bpb.b17-00291
18
HuC.RusinC. G.TanZ.GuagliardoN. A.BarrettP. Q. (2012). Zona glomerulosa cells of the mouse adrenal cortex are intrinsic electrical oscillators. J. Clin. Invest.122, 2046–2053. doi: 10.1172/JCI61996
19
KomiciK.RengoG.LeoscoD.FerraraN. (2017). Cardiac fibrosis in heart failure. J. Gerontology Geriatrics65, 177–183.
20
LoweJ. D.SandersonH. S.CookeA. E.OstovarM.TsisanovaE.WitheyS. L.et al. (2015). Role of G protein-coupled receptor kinases 2 and 3 in μ-opioid receptor desensitization and internalization. Mol. Pharmacol.88 (2), 347–356. doi: 10.1124/mol.115.098293
21
MarneyA. M.BrownN. J. (2007). Aldosterone and end-organ damage. Clin. Sci. (Lond.)113, 267–278. doi: 10.1042/CS20070123
22
MayorF.Jr.LucasE.Jurado-PueyoM.Garcia-GuerraL.Nieto-VazquezI.Vila-BedmarR.et al. (2011). G Protein-coupled receptor kinase 2 (GRK2): a novel modulator of insulin resistance. Arch. Physiol. Biochem.117, 125–130. doi: 10.3109/13813455.2011.584693
23
PitcherJ. A.TesmerJ. J.FreemanJ. L.CapelW. D.StoneW. C.LefkowitzR. J. (1999). Feedback inhibition of G protein-coupled receptor kinase 2 (GRK2) activity by extracellular signal-regulated kinases. J. Biol. Chem.274 (49), 34531–34534. doi: 10.1074/jbc.274.49.34531
24
PittB.ZannadF.RemmeW. J.CodyR.CastaigneA.PerezA.et al. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med.341, 709–717. doi: 10.1056/NEJM199909023411001
25
ReddyN. M.MahajanU. B.PatilC. R.AgrawalY. O.OjhaS.GoyalS. N. (2015). Eplerenone attenuates cardiac dysfunction and oxidative stress in β-receptor stimulated myocardial infarcted rats. Am. J. Transl. Res.7, 1602–1611.
26
SchrierR. W.MasoumiA.ElhassanE. (2010). Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin. J. Am. Soc. Nephrol.5, 1132–1140. doi: 10.2215/CJN.01410210
27
ShafiqM. M.MillerA. B. (2009). Blocking aldosterone in heart failure. Ther. Adv. Cardiovasc. Dis.3, 379–385. doi: 10.1177/1753944709341300
28
SpätA.HunyadyL. (2004). Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol. Rev.84, 489–539. doi: 10.1152/physrev.00030.2003
29
StockandJ. D.MeszarosJ. G. (2003). Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am. J. Physiol. Heart Circ. Physiol.284, H176–H184. doi: 10.1152/ajpheart.00421.2002
30
SwedbergK.EnerothP.KjekshusJ.WilhelmsenL. (1990). Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Consensus Trial Study Group Circulation82, 1730–1736. doi: 10.1161/01.CIR.82.5.1730
31
TianJ.ShidyakA.PeriyasamyS. M.HallerS.TalebM.El-OkdiN.et al. (2009). Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin. Hypertension54, 1313–1320. doi: 10.1161/HYPERTENSIONAHA.109.140038
32
VerhovezA.WilliamsT. A.MonticoneS.CrudoV.BurrelloJ.GalmozziM.et al. (2012). Genomic and non-genomic effects of aldosterone. Current Signal Transduction Therapy7, 132–141. doi: 10.2174/157436212800376708
33
WadaT.OhshimaS.FujisawaE.KoyaD.TsunekiH.SasaokaT. (2009). Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes. Endocrinology150, 1662–1669. doi: 10.1210/en.2008-1018
34
WeberK. T. (2001). Aldosterone in congestive heart failure. N. Engl. J. Med.345, 1689–1697. doi: 10.1056/NEJMra000050
35
ZannadF.McMurrayJ. J.KrumH.van VeldhuisenD. J.SwedbergK.ShiH.et al. (2011). Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med.364, 11–21. doi: 10.1056/NEJMoa1009492
Summary
Keywords
aldosterone, mineralocorticoid receptor, GRK2, insulin, β-adrenergic receptor, heart failure
Citation
Cannavo A, Marzano F, Elia A, Liccardo D, Bencivenga L, Gambino G, Perna C, Rapacciuolo A, Cittadini A, Ferrara N, Paolocci N, Koch WJ and Rengo G (2019) Aldosterone Jeopardizes Myocardial Insulin and β-Adrenergic Receptor Signaling via G Protein-Coupled Receptor Kinase 2. Front. Pharmacol. 10:888. doi: 10.3389/fphar.2019.00888
Received
23 January 2019
Accepted
15 July 2019
Published
09 August 2019
Volume
10 - 2019
Edited by
Yuichi Hattori, University of Toyama, Japan
Reviewed by
Federico Mayor, Autonomous University of Madrid, Spain; Luciana Venturini Rossoni, University of São Paulo, Brazil
Updates
Copyright
© 2019 Cannavo, Marzano, Elia, Liccardo, Bencivenga, Gambino, Perna, Rapacciuolo, Cittadini, Ferrara, Paolocci, Koch and Rengo.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alessandro Cannavo, alessandro.cannavo@unina.it
†The authors have contributed equally to this work.
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.